New Tuberculosis Drug May Shorten Treatment Time For Patients

2019-02-12 11:55:39



A new experimental antibiotic for tuberculosis has been shown to be more effective against TB than isoniazid, a decades-old drug which is currently one of the standard treatments. In mouse studies, the new drug showed a much lower tendency to develop resistance, and it remains in the tissues where the Mycobacterium tuberculosis bacteria reside for longer, killing them more effectively. The research is published in Antimicrobial Agents and Chemotherapy, a journal of the American Society for Microbiology.

The goal of TB drug development programs is to develop universal treatment regimens that will shorten and simplify TB treatment in patients, which typically takes at least six months, and sometimes more than a year, said lead author Gregory T. Robertson, PhD, Assistant Professor, Department of Microbiology, Immunology, and Pathology, Colorado State University, Fort Collins.

The new drug, called AN12855, has several advantages over isoniazid. Isoniazid, requires conversion to its active form by a Mycobacterial enzyme, KatG, in order to kill the pathogen, which creates a couple of problems. First, in some M. tuberculosis, KatG is nonfunctional. That doesn't make M. tuberculosis any less pathogenic, but it prevents the drug from working.

That creates an easy avenue for the development of drug resistance. Under selection pressure from isoniazid, the tuberculosis bacteria with nonfunctional KatG  those that don't activate the drug  are the ones that reproduce. Under these circumstances, drug resistance may develop.

A hallmark of human tuberculosis is the presence of "heterogeneous pulmonary disease." This includes a host defense involving confinement of invading bacteria within small cyst-like bodies called granulomas, that lack vasculature and often prevent the drug from reaching the pathogen. Most mouse TB models used for clinical evaluation of new drugs fail to produce this advanced lung pathology. Thus, they give little insight into how drugs might behave in the presence of advanced lung disease that is typical of human tuberculosis.

In the study, the investigators used a new TB mouse model that develops these M. tuberculosis-containing granulomas to compare isoniazid and AN12855. Researchers  discovered that the drugs differed dramatically with respect to their abilities to kill the pathogen in highly diseased tissues.